Nuwellis Postpones Second Quarter Earnings Release
Nuwellis, Inc. (Nasdaq: NUWE), a pioneering medical technology company specializing in fluid management, has announced a rescheduling of its second-quarter earnings release for the year 2025. Initially set for August 12, 2025, the company now requires additional time to conduct its essential valuations and allow its auditing firm to finalize related audit methods.
New Conference Call Details
To ensure shareholders are updated with the latest financial information and business strategies, Nuwellis plans to hold a conference call on August 14, 2025, at 9:00 AM ET. This live call will provide insights into the company’s recent performance and upcoming initiatives.
How to Join the Conference Call
Investors can access the live conference call by dialing 1-800-245-3047 within the U.S. or 1-203-518-9765 for international participants. To engage in the discussion, participants need to use the conference ID: NUWEQ2. In addition, a live webcast will be available on the Nuwellis Investors page. This will facilitate easy access for those who prefer virtual attendance.
Webcast Availability
Following the call, an audio recording of the webinar will be accessible on the company’s Investors page. This provides an opportunity for investors and interested parties to catch up on any discussions or announcements they may have missed.
Understanding Nuwellis and Its Mission
Nuwellis is dedicated to transforming the lives of patients suffering from fluid overload through innovative solutions. Its core focus lies in the commercialization of the Aquadex SmartFlow® system, designed to treat hypervolemia effectively. Headquartered in Minneapolis, the company operates with a forward-thinking approach, ensuring that they meet the dynamic needs of their patients.
Aquadex SmartFlow® System Overview
The Aquadex SmartFlow system represents a significant advancement in ultrafiltration therapy for those grappling with fluid overload conditions. This technology offers a safe and clinically proven platform that can flexibly remove excess fluids from patients. It is suitable for both adults and pediatric patients who weigh 20 kg or more and have not seen adequate results from conventional medical management, including diuretics. Treatments are administered by trained healthcare professionals within clinical settings, ensuring patient safety and efficacy.
Commitment to Innovation
Nuwellis continually seeks to innovate within the healthcare landscape. Their commitment to research and development in fluid management is steadfast, laying the groundwork for future advancements in patient care. The company's strategy revolves around collaboration with healthcare professionals and leveraging cutting-edge technology to address complex medical challenges.
Frequently Asked Questions
What is the new date for the Nuwellis earnings release?
The Nuwellis earnings release has been postponed to August 14, 2025.
How can I access the Nuwellis conference call?
You can join the conference call by dialing 1-800-245-3047 (U.S.) or 1-203-518-9765 (international) using conference ID: NUWEQ2.
What is the purpose of the Aquadex SmartFlow system?
The Aquadex SmartFlow system is designed to remove excess fluid from patients suffering from hypervolemia using a clinically proven therapeutic approach.
Where is Nuwellis located?
Nuwellis is headquartered in Minneapolis, with operations that extend to a wholly owned subsidiary in Ireland.
How does Nuwellis plan to innovate in fluid management?
Nuwellis focuses on research and development, collaborating with healthcare professionals to introduce cutting-edge solutions that effectively address fluid overload in patients.